ACXP

$1.44-$0.06 (-3.90%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$6.6M

4M shares

52-week range

$1.33 – $8.34

2% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-83.12

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$276000	-97.3%	$-1.65	$-1.65–$-1.65	—	1
2027	$4M	+1180.8%	$-1.77	$-1.77–$-1.77	—	1
2028	$25M	+615.9%	$-2.02	$-2.02–$-2.02	—	1
2029	$47M	+87.7%	$-1.76	$-1.76–$-1.76	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 5 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-14	$-0.38	$-0.53	-40.7%
2026-05-12	$-0.59	$-0.62	-5.1%
2026-03-13	$-1.01	$-0.31	+69.3%
2025-11-12	$-1.61	$-1.23	+23.6%
2025-08-11	$-2.00	$-1.89	+5.5%
2025-05-12	$-0.15	$-2.20	-1366.7%
2025-03-17	$-0.18	$-0.16	+11.1%
2024-11-12	$-0.23

DCF fair valuemodel estimate

Intrinsic value

$5040.79

Price

$1.44

Implied upside

+351175%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ACXPAcurx Pharmaceuticals, Inc.	$1.48	-3.90%	$6M	—
ADILAdial Pharmaceuticals, Inc.	$4.39	+1.86%	$4M	—
APREAprea Therapeutics, Inc.	$0.67	-1.76%	$8M	—
APVOAptevo Therapeutics Inc.	$3.40	-2.86%	$7M	—
BCDABioCardia, Inc.	$0.93	+5.56%

Acurx Pharmaceuticals, Inc. Common Stock

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

www.acurxpharma.com

Employees: 4
IPO / List date: Jun 25, 2021
HQ: STATEN ISLAND, NY

Held by traders on TradeandTell

No one on the platform currently holds ACXP.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ACXP as of their last filing.

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Stock splits

Execution date	Ratio
2025-08-05	1-for-20reverse

Recent trades on TradeandTell

No one on the platform has traded ACXP yet.

$ACXP chatter on StockTwits

jorge .miguel@focafoca9938m
$ACXP is reporting Q2 2026 results, closing a $2.5M direct offering and ending the quarter with $10.7M cash.
View on StockTwits ↗
Sam@Toptradersam2h
$BAOS $ACXP $ONFO $CAST $DARE This one is back on my radar! 📈 I’m watching for a potential high-volatility bounce and looking for the right entry instead of chasing the spike. https://www.youtube.com/watch?v=EpAfFgljOJY
View on StockTwits ↗
아잇@dpdlwnl12Bullish1d
$ACXP is expected to surge this afternoon. 🚀🚀🚀 Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program. According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections.
View on StockTwits ↗
아잇@dpdlwnl12Bullish1d
$VBIO $ACXP is expected to surge this afternoon. 🚀🚀🚀 Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program. According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections.
View on StockTwits ↗
아잇@dpdlwnl12Bullish1d
$WCT $ACXP is expected to surge this afternoon. 🚀🚀🚀 Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program. According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections..
View on StockTwits ↗
아잇@dpdlwnl12Bullish1d
$SBEV $ACXP is expected to surge this afternoon. 🚀🚀🚀 Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program. According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections.
View on StockTwits ↗
아잇@dpdlwnl12Bullish1d
$BIVI $ACXP is expected to surge this afternoon. 🚀🚀🚀 Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program. According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections...
View on StockTwits ↗
아잇@dpdlwnl121d
$OFAL $ACXP is expected to surge this afternoon. 🚀🚀🚀 Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program. According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections..
View on StockTwits ↗
아잇@dpdlwnl121d
$RMCF $ACXP is expected to surge this afternoon. 🚀🚀🚀 Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program. According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections.
View on StockTwits ↗
james olson@ballyhoooBullish3d
$ACXP Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics
View on StockTwits ↗
Matty Ice@Woodpecker99Bullish6d
$ACXP what’s everyone’s PT here?
View on StockTwits ↗
Aura@ExploringTradesAug 4
Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $PUSA $ACXP Pola
View on StockTwits ↗
Edward .DR@MarketForecastingBearishAug 3
$ACXP what fools these stooges are , putting the cart before the horse.
View on StockTwits ↗
STACKD0E@STACKD0EBullishAug 3
$ACXP 👁
View on StockTwits ↗
james olson@ballyhoooBullishAug 3
$ACXP just approve it already...it actually works!
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.